Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib & Lucitanib

 Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib & Lucitanib

Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib & Lucitanib

Shots:

  • The companies enter into an agreement to jointly evaluate safety & efficacy of Alkermes’ ALKS 4230 in combination with Clovis Oncology’s Rucaparib & Lucitanib with equal cost sharing in preclinical studies, in patients with multiple tumors
  • The focus of the agreement is for the onset of preclinical program for exploring anti-cancer effects of the combination therapy in multiple tumors, through PARP and tyrosine kinase inhibition pathways
  • ALKS 4230 is an interleukin-2 (IL-2) variant immunotherapy targeted for activating tumor-killing immune cells. Rucaparib is an oral PARP inhibitor, stimulating an anti-tumor immune response on tumor cells. Lucitanib is a tyrosine kinase inhibitor of VEGFR1-3 & FGFR1-3

Click here to read full press release/ article| Ref: Clovis Oncology | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post